Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek minimum 18 lat
- •Potwierdzony histologicznie rak płuca bez drobnych komórek
- •Przerzuty do mózgu (aktywne zmiany są dozwolone)
- •Potwierdzona mutacja genu ROS1 w certyfikowanym laboratorium
- •Zdolność połykania kapsułek w całości
- •Stan ogólny zdrowia pozwalający na uczestnictwo (ECOG ≤ 2)
- •Oczekiwana długość życia co najmniej 6 tygodni
- •Frakcja wyrzutowa lewej komory serca ≥ 50%
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (17)
Medizinische Universität Graz
Graz, Austria
Medical University of Vienna
Vienna, Austria
Ludwig-Maximilians-University Munich
München, Germany
Hospital de Vinalopó
Elche, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
UOMI Cancer Center
Barcelona, Spain
Institut Català d' Oncologia Girona (ICO)
Girona, Spain
Hospital Beata María Ana
Madrid, Spain
Hospital Universitari Sant Joan de Reus
Reus, Spain
Hospital General Universitario Dr. Balmis
Alicante, Spain
Hospital de Cruces
Barakaldo, Spain
Hospital Universitario de León
León, Spain
Hospital Lucus Agusti
Lugo, Spain
Hospital Universitario Vithas Madrid La Milagrosa
Madrid, Spain
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain
Complejo Hospitalario Universitario de Santiago (CHUS)
Santiago de Compostela, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.